These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32007322)

  • 1. Adjuvant antithrombotic therapy in ST-elevation myocardial infarction: Contemporaneous Portuguese cross-sectional data.
    Caldeira D; Pereira H; Marques A; Alegria S; Calisto J; Silva PCD; Ribeiro VG; Silva JC; Seixo F; Abreu PFE; Teles RC; Fernandes R; Carvalho HC;
    Rev Port Cardiol (Engl Ed); 2019 Nov; 38(11):809-814. PubMed ID: 32007322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant antithrombotic therapy in ST-elevation myocardial infarction: A narrative review.
    Caldeira D; Pereira H
    Rev Port Cardiol (Engl Ed); 2019 Apr; 38(4):289-297. PubMed ID: 31122865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current patterns of antithrombotic and revascularisation therapy in patients hospitalised for acute coronary syndromes. Data from the Polish subset of the EPICOR study.
    Wojtkowska I; Stępińska J; Stępień-Wojno M; Sobota M; Kopaczewski J; Reszka Z; Kurzelewski M; Medina J
    Kardiol Pol; 2017; 75(5):445-452. PubMed ID: 28281731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing adjunctive antithrombotic and anticoagulant therapy in primary PCI for STEMI.
    Deharo P; Rahbi H; Cuisset T
    Minerva Cardioangiol; 2016 Jun; 64(3):238-55. PubMed ID: 26934662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of ST-segment elevation myocardial infarction in patients with atrial fibrillation, prior stenting and long-standing chronic coronary syndrome.
    Franchina AG; Calderone D; D'Arrigo P; Ingala S; Milluzzo RP; Greco A; Spagnolo M; Tamburino C; Capodanno D
    Cardiol J; 2020; 27(1):8-15. PubMed ID: 31960945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal Antithrombotic Therapy for Patients with STEMI Undergoing PCI at High Risk of Bleeding.
    Tu Y; Hu L; Yang C; Nemat A; Xian G; Zhang J; Zeng Q
    Curr Atheroscler Rep; 2019 Apr; 21(6):22. PubMed ID: 30997584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic therapy for patients with STEMI undergoing primary PCI.
    Franchi F; Rollini F; Angiolillo DJ
    Nat Rev Cardiol; 2017 Jun; 14(6):361-379. PubMed ID: 28230176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of prehospital administration of unfractionated heparin, enoxaparin or bivalirudin in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Insights from the ORBI registry.
    Auffret V; Leurent G; Boulmier D; Bedossa M; Zabalawi A; Hacot JP; Coudert I; Filippi E; Castellant P; Rialan A; Rouault G; Druelles P; Boulanger B; Treuil J; Avez B; Le Guellec M; Gilard M; Le Breton H
    Arch Cardiovasc Dis; 2016 Dec; 109(12):696-707. PubMed ID: 27818120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction-a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial).
    Erlinge D; Koul S; Eriksson P; Scherstén F; Omerovic E; Linder R; Östlund OP; Wallentin L; Fröbert O; James S
    Am Heart J; 2016 May; 175():36-46. PubMed ID: 27179722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
    Cohen M
    Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
    Silva MA; Donovan JL; Gandhi PJ; Volturo GA
    Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States.
    Secemsky EA; Kirtane A; Bangalore S; Jovin IS; Shah RM; Ferro EG; Wimmer NJ; Roe M; Dai D; Mauri L; Yeh RW
    JACC Cardiovasc Interv; 2016 Dec; 9(23):2376-2386. PubMed ID: 27838271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention.
    Wang TY; Magid DJ; Ting HH; Li S; Alexander KP; Roe MT; Peterson ED
    Am Heart J; 2014 Jun; 167(6):833-9. PubMed ID: 24890532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances in Optimal Adjunctive Antithrombotic Therapy in STEMI Patients Undergoing Primary Angioplasty: An Overview.
    De Luca G; Suryapranata H
    Curr Vasc Pharmacol; 2015; 13(5):594-615. PubMed ID: 25543899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic strategies in the catheterization laboratory for patients with acute coronary syndromes undergoing percutaneous coronary interventions: insights from the EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitalized in iTalian cardiac care units Registry.
    De Luca L; Musumeci G; Leonardi S; Gonzini L; Cavallini C; Calabrò P; Mauro C; Cacciavillani L; Savonitto S; De Servi S;
    J Cardiovasc Med (Hagerstown); 2017 Aug; 18(8):580-589. PubMed ID: 28639987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study.
    De Luca L; Leonardi S; Cavallini C; Lucci D; Musumeci G; Caporale R; Abrignani MG; Lupi A; Rakar S; Gulizia MM; Bovenzi FM; De Servi S;
    Eur Heart J Acute Cardiovasc Care; 2015 Oct; 4(5):441-52. PubMed ID: 25414322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bivalirudin versus heparin with primary percutaneous coronary intervention.
    Venetsanos D; Lawesson SS; James S; Koul S; Erlinge D; Swahn E; Alfredsson J
    Am Heart J; 2018 Jul; 201():9-16. PubMed ID: 29910059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
    Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
    Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
    Gibson CM; Murphy SA; Montalescot G; Morrow DA; Ardissino D; Cohen M; Gulba DC; Kracoff OH; Lewis BS; Roguin N; Antman EM; Braunwald E;
    J Am Coll Cardiol; 2007 Jun; 49(23):2238-46. PubMed ID: 17560287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controversies in the Management of ST Elevation Myocardial Infarction: Thrombin Inhibition.
    Shah N; Cox D
    Interv Cardiol Clin; 2016 Oct; 5(4):497-511. PubMed ID: 28581998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.